Li H, Cao HF, Li Y, Zhu ML, Wan J. Changes in gene-expression profiles of colon carcinoma cells induced by wild type K-ras2. World J Gastroenterol 2007; 13(34): 4620-4625 [PMID: 17729418 DOI: 10.3748/wjg.v13.i34.4620]
Corresponding Author of This Article
Jun Wan, Department of South Building Gastroenterology, General Hospital of Chinese PLA, Beijing 100083, China. wanjun@301hospital.com.cn
Article-Type of This Article
Rapid Communication
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Hong Li, Hou-Fa Cao, Inpatient Department of Special Need Treatment, General Hospital of Chinese PLA, Beijing 100083, China
Yuan Li, Mei-Ling Zhu, Jun Wan, Department of South Building Gastroenterology, General Hospital of Chinese PLA, Beijing 100853, China
ORCID number: $[AuthorORCIDs]
Author contributions: All authors contributed equally to the work.
Supported by National Natural Science Foundation of China, No. 30200326
Correspondence to: Jun Wan, Department of South Building Gastroenterology, General Hospital of Chinese PLA, Beijing 100083, China. wanjun@301hospital.com.cn
Telephone: +86-10-66937584 Fax: +86-10-66937584
Received: March 15, 2007 Revised: June 20, 2007 Accepted: June 23, 2007 Published online: September 14, 2007
Abstract
AIM: To further elucidate the possible molecular biological activity of wild type K-ras2 gene by detecting changes in wild type K-ras2 gene-induced gene-expression profiles of colon carcinoma cells using cDNA microarray techniques.
METHODS: Total RNA was isolated from peripheral blood of health volunteers. Reverse transcription of RNA and polymerase chain reaction were used to synthesize wild type K-ras2 cDNA. K-ras2 cDNA fragment was cloned into a T easy vector and sequenced. A eukaryotic expression vector pCI-neo-K-ras2 was constructed and transfected to Caco2 cell line using the liposome method. Finally, mRNA was isolated, reverse-transcribed to cDNA from pCI-neo-K-ras2 or pCI-neo blank vector-transfected Caco cells, and analyzed by cDNA microarray assay.
RESULTS: Restriction enzyme analysis and DNA sequencing verified that the constructed expression vector was accurate. High-quality RNA was extracted and reverse transcribed to cDNA for microarray assay. Among the 135 genes, the expression was up-regulated in 24 and down-regulated in 121. All these differentially expressed genes were related to cell proliferation, differentiation, apoptosis and signal transduction.
CONCLUSION: Differentially expressed genes can be successfully screened from wild type K-ras2-transfected colon carcinoma cells using microarray techniques. The results of our study suggest that wild type K-ras2 is related to the negative regulation of cell proliferation, metabolism and transcriptional control, and provide new clues to the further elucidation of its possible biological activity.
Citation: Li H, Cao HF, Li Y, Zhu ML, Wan J. Changes in gene-expression profiles of colon carcinoma cells induced by wild type K-ras2. World J Gastroenterol 2007; 13(34): 4620-4625
Carcinogenesis and progression of human colon carcinoma result from abnormal expression of many tumor-associated genes. Activation oncogenes and deactivation antioncogenes are known as one of their important mechanisms[1,2]. Ras gene which is closely related to carcinogenesis and progression of colon carcinoma consists of three members: Hras1, Nras and K-ras2[3,4]. It is traditionally believed that activated Ras gene plays a dominant role as an oncogene in the pathogenesis of colon carcinoma. About 30% of tumors display mutations of Ras gene members, the most frequent mutation is found in K-ras2[5,6], and the relatively high frequency of K-ras2 mutation is observed in colon, pancreas and lung carcinomas[7-9]. Recent studies indicate that frequent loss of wild type Ras gene occurs in human and mouse lung adenocarcinomas, thus questioning the dominant role of Ras gene in the pathogenesis of tumors[10]. Loss of heterozygosity on chromosome 12p12-13 in K-ras2 gene has also been found in non-small-cell lung cancer[11,12]. We have reported that frequent loss of heterozygosity occurs in this domain during carcinogenesis and progression of colon carcinoma[13]. By observing the changes in growth curve and cell cycle of colon carcinoma cells transducted with wild type K-ras2 gene, we found that wild type K-ras2 gene could step down the growth and cell cycle of colon carcinoma cells manifested as significantly increased stage G0-G1 cells and decreased stage G2-M cells, suggesting that resting cells with proliferation activity are inhibited to advance into proliferating cell cycle[14]. In the present study, in order to study the biological activity of wild type K-ras2 gene, we constructed a eukaryotic expression vector of wild type K-ras2 gene phenotype, screened differentially expressed genes of colon carcinoma cells transfected by wild K-ras2 gene with cDNA microarray, and detected the effect of wild K-ras2 on the gene-expression profiles of colon carcinoma and its function in vivo. The results provide new clues to the exploration of the pathogenesis of colon carcinoma and the functions of K-ras2 gene.
MATERIALS AND METHODS
Cells and cDNA array
Human colon adenocarcinoma cell line Caco-2 was obtained from the ATCC. DMEM, FBS, Trizol RNA isolation kit, pCI-neo mammalian expression vector and Lipofectamine2000 were purchased form Invitrogen (Carlsbad, CA). A commercial human expression cDNA array was obtained from Shanghai Biochip Company (Shanghai, China). The array includes 8568 known genes, which can be categorized into cell division, cell signaling, cell structure, gene and protein expression, metabolism and pseudogene, etc.
Transfection of Caco-2 cells
Total RNA was isolated from peripheral blood of health volunteers using Trizol RNA isolation kit. Reverse transcription of RNA and polymerase chain reaction were used to synthesize the full-length sequence of wild K-ras2 cDNA. Primers containing Mul1 and Sal1 restrictions (Y1: 5'-ACCCACGCGTATGACTGAATATAAAC-3'; Y2: 5'-AACGTCGACTTACATAATTACACACT-3') were synthesized by Shanghai Ouke Biotech Company (Shanghai, China). The PCR products were inserted into pGEM-T Easy vector (Promega) to generate pGEM-T-Ras, and positive clones were identified by blue/white color screening followed by sequencing. pGEM-T-Ras and pCI-neo eukaryotic expression vector were digested in Mul1 and Sal1 restriction enzymes and ligated using T4 DNA ligase (Promega) to produce pCI-neo-K-ras2. The recombinant pCI-neo-K-ras2 and empty pCI-neo-K-ras2 were transfected into Caco-2 cells (ATCC) using Lipofectamine2000 according to the manufacturer’s instructions, and the positive clones were selected from G418 (Amresco).
cDNA microarray analysis
Total RNA was extracted from pCI-neo-K-ras2 (transfection group) and empty pCI-neo-K-ras2 (control group) using Trizol RNA isolation kit. The purity of RNA was confirmed by agarose gel electrophoresis and absorbance (A) ratio (A260/A280). To make cDNA probes, approximately 5 μg of total RNA was labeled with Cy3-dUTP (control) or Cy5-dUTP (transfection group) by reverse transcription. The probes were precipitated using ethanol and dissolved in 5 × SSC + 2 g/L SDS at 20°C. The microarray and probes were denatured in 95°C water bath for 5 min. Hybridization was performed at 60°C for 15-17 h. Microarray was washed with 2 × SSC + 2 g/L SDS and 1 × SSC + 2 g/L SDS for 10 min respectively and dried at room temperature. Scanning was performed with ScanArray3000 (General Scanning, Inc.). The acquired image was analyzed using ImaGene 3.0 software (BioDiscovery, Inc.). The intensities of Cy3-dUTP and Cy5-dUTP were normalized by a coefficient according to the ratio of housekeeping genes. The positively expressed genes were as follows: Cy5-dUTP: Cy3-dUTP signal ratio > 2.0, red fluorescent displaying up-regulated expression; Cy5-dUTP: Cy3-dUTP signal ratio < 0.5, green fluorescent displaying down-regulated expression.
Statistical analysis
Data on gene expression were analyzed by Student’s t test using SPSS 10.0 software and P < 0.05 was considered statistically significant.
RESULTS
Validation of wild type K-ras2 and RNA
Restriction enzyme analysis and nucleotide sequencing of eukaryotic expression vector pCI-neo-K-ras2 showed that its sequence containing an integrity open reading frame was accurate (Figure 1). A 260/A280 of total RNA ranging from 1.9 to 2.1 and 28S/18S of about 2 indicated that RNA was not degraded and could be used for preparation of hybridization probe (Figure 2).
Figure 2 Electropherogram of total RNA from control (A) and transfection (B) groups.
Results verified by microarray hybridization system
To monitor the whole process of microarray hybridization, we set up 6 negative controls and 10 positive controls. Scanning of hybridization array and report of array detection showed that hybridization array and sample RNA were intact with good background value and well-distributed noise. The hybridization reaction system was normal and the results were reliable. To compare gene profiles between transfection and control groups, a scatter profile was plotted for the probe signal values, showing that most genes were distributed around the regression line, and their expression in two tissue samples was similar, but a few genes had a different expression. When the difference in gene expression increased, the number of differently expressed genes decreased (Figure 3). The data were confirmed by the low hybridization signal of these genes. Cy5 fluorescein (red) and Cy3 fluorescein (green) were used to mark the probes of experimental and control groups, and the difference in color was expressed as the difference in gene expression between the two groups. Yellow indicated no expression difference. According to the experimental protocol, the expression of 24 genes with their cy5/cy3 ≥ 2 (Table 1) was up-regulated, accounting for 17.76% of all the differentially expressed genes, and the expression of 121 genes with their cy5/cy3 ≤ 0.5 was down-regulated, accounting for 89.63% of all the differentially expressed genes. The top 30 down-regulated genes are listed in Table 2.
Table 1 Biological function of genes with down-regulated expression.
Gene
Chromosomal localization
Biological function
Cy5/Cy3
NDP
Xp11.4
Cross-cell signal transmission, signal transduction, NS development
4.509
SSX4
Xp11.23
Transcription regulation, immunoreaction
4.044
CASP1
11q23
Positive regulation of I-kappaB kinase/NF-kappaB cascadereaction, signal transduction, apoptosis
Figure 3 Scatter bar of gene-expression profiles of Caco2 cells transfected (A) and non-transfected (B) with wild-type K-ras2 gene.
Biological function classification of differentially expressed wild type K-ras2 genes Biological function classification of differentially expressed wild type K-ras2 genes was performed based on the biological classification of genes in Affymetrix gene ontology database. Eleven subtypes were found to be closely related to carcinogenesis (Table 3).
Table 3 Functional classification of differentially expressed genes.
Type of gene
Down-regulatedgenes (n)
Rate ofdown-regulatedgenes (%)
Up-regulatedgenes (n)
Rate ofup-reguletedgenes (%)
Metabolism-associated
18
14.88
3
12.50
Cell proliferation
30
24.79
3
12.50
Cell cycle
16
13.22
0
0
Signal transduction
18
14.88
8
33.30
Cytokelet
8
6.61
1
4.17
Transcription control
18
14.88
4
16.67
Cell adhere
11
9.09
1
4.17
Cell apoptosis
8
6.61
2
8.33
Cell differentiation
14
11.57
4
16.67
Immune-associated
14
11.57
2
8.33
ECM
6
4.96
1
4.17
DISCUSSION
Carcinogenesis and progression of colon cancer represent its phases from normal mucosa to atypical hyperplasia (including intestinal metaplasia) of adenoma and adenocarcinoma, involving multiple genes and factors[15]. K-ras2 gene plays a dominant role as an oncogene in promoting carcinogenesis because of point mutation[16,17]. In the present study, in vitro experiments demonstrated that carcinogenic agents used in the treatment of loss of heterozygosity in mice with wild type K-ras2 gene facilitated the development of cancer but not in those with normal wild phenotype K-ras2 gene. Moreover, the size of poorly-differentiated adenocarcinoma in mice with loss of heterozygosity was significantly larger than that of adenoma in mice with abnormal wild phenotype K-ras2 gene. It was reported that cell lines activated by wild type K-ras2 gene-transfected ras can inhibit cell growth, clone formation and tumorigenesis in nude mice, indicating that wild type K-ras2 gene may be a potential anti-oncogene[9,18]. Changes in gene-expression of Caco2 cells induced by wild type K-ras2 gene were found in our study, showing the possible biological activity of wild type K-ras2 gene.
In our study, genes related to signal transduction, transcription control and cell differentiation were dominant, accounting for 33.33% of the total up-regulated genes. The top 30 down-regulated genes related to cell proliferation accounted for 24.79% of the total up-regulated genes. The expression of genes related to cell metabolism, cell cycle and transcription control was up-regulated. Wild type ras may inhibit cell proliferation by promoting differentiation. In fact, it has long been known that Ras proteins can induce differentiation of some cell types, such as neurons, under certain conditions[19]. Our findings suggest that K-ras2 can negatively regulate cell proliferation, metabolism and transcription control, and inhibit the growth of colon carcinoma.
The expression of NDP is most significant. As a genetic locus, its mutation may give rise of genetic-correlated Norrie disease caused by two molecular defects in NDP gene. One is 265 C>G missense mutation in the 97th codon by changing arginine into praline, the other is excalation in 3'-non-translated region of the third exon[20]. It was reported that patients with gene excalation present relatively severe symptoms, whereas patients with gene mutation display relatively mild symptoms[21]. The SSX4 gene (a member of the node point protein family) whose expression was significantly up-regulated in our study, can inhibit cell transcription, cause humor- and cell-mediated immune reaction, and may be a very valuable target for vaccine therapy of tumors[22]. Caspase-1 encoding apoptosis-associated thioserinase (a member of the caspase family) can lead to proteolysis and activate pro-IL-1, thus playing an important role in cell apoptosis[23]. Its up-regulated expression in wild-type K-ras2-transducted cells may be related to apoptosis of tumor cells, suggesting that caspase-1 is one of the human p53-dependent cell modulators[24].
The myc gene whose expression was most significantly up-regulated in our study, is closely related to tumors. It is adjusted by many factors, and can promote cell mitosis and make target cells proliferate and immortalize. This gene involving cell apoptosis is related to tumorigenesis and progression of diverse tumors[25]. Amplification of correlated sequence of myc has been observed in diverse human tumor cell lines including cell lines of granulocytic leukemia, retinoblastoma, neuroblastoma, breast and lung cancer, as well as in human colon carcinoma cell line[26,27]. The MMP14 gene (MT1-MMP) is a member of the matrix metalloprotease family. Its function is modified and regulated by O-glycosylation, interaction with CD44, internalization and recycling, depending on its proper expression on the cell surface[28]. It can invade tumors by activating MMP2 protein. It was reported that up-regulated expression of MMP2 and MT1-MMP is related to invasion of glioblastoma[29], while the expression of MT1-MMP is related to local invasion of and metastasis to lymphonodes of oral squamous cell carcinoma[30], supporting its function in colon carcinoma LoVo cells[31]. The WIT-1 gene is localized in the upstream of Wilm’s tumor gene sharing the same promoter. Methylation of the WIT-1 gene is related to chemotherapy-resistant tumors and acute leukemia[32]. The EPHB4 gene whose expression was remarkably down-regulated in our study is a member of the biggest receptor tyrosine kinase (RTK) family. Its encoding protein, a receptor of ephrin-B2, promotes microvascular endothelial cell migration and/or proliferation, thus playing an important role in angiogenesis of tumors[33]. It has been shown that EPHB4 expresses in diverse tumors such as prostate carcinoma and astrocytoma, and involves phenotype transformation post-metastasis[34,35].
In summary, K-ras2 seems to have a dual function. On the one hand, it promotes cancer development as a gain of function oncogene. On the other hand, it inhibits cancer as a loss-of-function tumor suppressor gene. There are some interesting parallels between the Trp53 tumor suppressor gene and the unfolding story of K-ras2. Trp53 was initially described as an oncogene carrying point mutations in tumors. Later, it was found that it is in fact the wild type copy of the gene that functions as a tumor suppressor gene and is capable of reducing cell proliferation. In this case, the Trp53 mutation may, in a sense, also be considered an activating (but not necessarily gain-of-function) mutation in that it produces a dominant-negative effect over the wild type p53 protein. The two major players in human cancer have more in common than they were previously thought[18].
COMMENTS
Background
Studies indicate that mutation of the K-ras2 gene plays an important role in carcinogenesis and progression of tumors. It was reported that K-ras2 gene not only induces tumors but also inhibits tumor growth. We have reported that loss of heterozygosity on chromosome 12p12-13 K-ras2 gene occurs in colon carcinoma and wild type K-ras2 gene can effectively inhibit its growth. This study was to construct a eukaryotic expression vector of the wild type K-ras2 gene phenotype, screen differentially expressed genes of colon carcinoma cells transfected by the wild K-ras2 gene with cDNA microarray, and detect the effect of wild K-ras2 gene on the gene-expression profiles of colon carcinoma and its function in vivo.
Research frontiers
Based on the results of recent studies, it is hypothesized that K-ras gene plays a role both in carcinogenesis and in inhibition of cancer. It is a poto-oncogene in normal physiological conditions. However, when mutations occur, the activated K-ras2 gene changes into an oncogene and wild type K-ras2 gene becomes an anti-oncogene. This is what we want to prove in this study.
Innovations and breakthroughs
Since the inhibitory effect of wild type K-ras2 gene on tumors was reported by Zhong-Qiu Zhang, its role in suppressing long cancer has been extensively studied by foreign scholars. This is the first time to study the inhibitory effect of wild type K-ras2 gene on colon carcinoma in China.
Applications
The possible molecular pathway of K-ras2 gene in suppressing tumor cell proliferation found in this study may contribute to finding the genes closely related with colon cancer.
Peer review
This interesting paper investigated the importance of K-ras cascade at mRNA level. The major finding of this study is that wild-type K-ras results in both complex induction and more common inhibition of several genes, and may have a dual role in carcinogenesis. The new association elucidated herein may provide further insight into the carcinogenesis and may identify potentially important therapeutic targets.
Bezieau S, Devilder MC, Avet-Loiseau H, Mellerin MP, Puthier D, Pennarun E, Rapp MJ, Harousseau JL, Moisan JP, Bataille R. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.Hum Mutat. 2001;18:212-224.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 143][Cited by in F6Publishing: 148][Article Influence: 6.4][Reference Citation Analysis (0)]
Halatsch ME, Hirsch-Ernst KI, Weinel RJ, Kahl GF. Differential activation of the c-Ki-ras-2 proto-oncogene in human colorectal carcinoma.Anticancer Res. 1998;18:2323-2325.
[PubMed] [DOI][Cited in This Article: ]
Deramaudt T, Rustgi AK. Mutant KRAS in the initiation of pancreatic cancer.Biochim Biophys Acta. 2005;1756:97-101.
[PubMed] [DOI][Cited in This Article: ]
Kim DH, Kim JS, Park JH, Lee SK, Ji YI, Kwon YM, Shim YM, Han J, Park J. Relationship of Ras association domain family 1 methylation and K-ras mutation in primary non-small cell lung cancer.Cancer Res. 2003;63:6206-6211.
[PubMed] [DOI][Cited in This Article: ]
Li H, Wan J, Li Y, Zhu ML, Zhao P. Loss of heterozygosity on chromosome 12p12-13 region in Chinese patients with colon carcinoma.Zhonghua YiXue YiChuanXue ZaZhi. 2005;22:694-697.
[PubMed] [DOI][Cited in This Article: ]
Zhu ML, Wan J, Li H, Li Y. Growth inhibitary effect of wild-type K-ras2 gene on colon adenocarcinoma cell.Junyi Jinxiu Xueyuan Xuebao. 2006;27:18-19.
[PubMed] [DOI][Cited in This Article: ]
Khan AO, Shamsi FA, Al-Saif A, Kambouris M. A novel missense Norrie disease mutation associated with a severe ocular phenotype.J Pediatr Ophthalmol Strabismus. 2004;41:361-363.
[PubMed] [DOI][Cited in This Article: ]
Kim YH, Girard L, Giacomini CP, Wang P, Hernandez-Boussard T, Tibshirani R, Minna JD, Pollack JR. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.Oncogene. 2006;25:130-138.
[PubMed] [DOI][Cited in This Article: ]
Kowara R, Gołebiowski F, Chrzan P, Skokowski J, Karmolinski A, Pawełczyk T. Abnormal FHIT gene transcript and c-myc and c-erbB2 amplification in breast cancer.Acta Biochim Pol. 2002;49:341-350.
[PubMed] [DOI][Cited in This Article: ]
Guo P, Imanishi Y, Cackowski FC, Jarzynka MJ, Tao HQ, Nishikawa R, Hirose T, Hu B, Cheng SY. Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 correlates with the invasiveness of human glioma.Am J Pathol. 2005;166:877-890.
[PubMed] [DOI][Cited in This Article: ][Cited by in Crossref: 84][Cited by in F6Publishing: 88][Article Influence: 4.6][Reference Citation Analysis (0)]
Xiao HL, Li ZP, Yin YS, Zhang QH, Jiang XF, Bian XW. Expressions of EphB4 receptor and its ligand ephrinB2 in brain astrocytoma and their value in prognosis.Disan Junyi Daxue Xuebao. 2005;18:49-52.
[PubMed] [DOI][Cited in This Article: ]
